A number of RAF inhibitors (RAFi) and MEK inhibitors (MEKi) are currently FDA approved for use in genomically selected cancers as well as Neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma19,27–29. The gene discussed is MAP2K7; the disease is cancer.